DeepMed Research

JANSSEN RESEARCH & DEVELOPMENT, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine

Completed

Conditions: Attention Deficit Disorder With Hyperactivity

Interventions: Drug: Amphetamine
Drug: Methylphenidate
Drug: Atomoxetine
Drug: Lisdexamfetamine
Drug: Dextroamphetamine

First Posted Date: 2019-10-21

Last Posted Date: 2019-11-08

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 430000

Registration Number: NCT04132557

Locations: 🇺🇸
Janssen Investigative Site, Titusville, New Jersey, United States

A Study of Subcutaneous Delivery of JNJ-54767414 in Chinese Participants With Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Daratumumab

First Posted Date: 2019-10-09

Last Posted Date: 2023-12-08

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 21

Registration Number: NCT04121260

Locations: 🇨🇳
Peking University Third Hospital, Beijing, China
🇨🇳
The Third Xiangya Hospital, Central South University, Changsha, China
🇨🇳
Nanfang Hospital, Guangzhou, China

and more 2 locations

A Study in Healthy Volunteers to Assess the Effect of Different Types of Food on a Single-dose of JNJ-64417184 Administered as Tablets

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: JNJ-64417184

First Posted Date: 2019-10-09

Last Posted Date: 2020-01-28

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 20

Registration Number: NCT04121052

Locations: 🇳🇱
PRA Health Sciences Onderzoekscentrum Groningen, locatie Martini, Groningen, Netherlands

Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia

Phase 2

Recruiting

Conditions: Warm Autoimmune Hemolytic Anemia

Interventions: Drug: M281
Drug: Placebo

First Posted Date: 2019-10-08

Last Posted Date: 2025-05-23

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 111

Registration Number: NCT04119050

Locations: 🇨🇳
Jiangsu Province Hospital, Nanjing, China
🇨🇳
Affiliated Hospital of Nantong University, Nantong, China
🇨🇳
Shanghai Zhongshan Hospital, ShangHai, China

and more 168 locations

A Study of Label Compliance for Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japan

Completed

Conditions: Attention Deficit Disorder With Hyperactivity

Interventions: Drug: Guanfacine (GFC)
Drug: MPH (Concerta)
Drug: MPH (Ritalin)
Drug: Atomoxetine (ATO)

First Posted Date: 2019-10-02

Last Posted Date: 2025-04-27

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 17418

Registration Number: NCT04113551

Locations: 🇺🇸
Janssen Investigative Site, Titusville, New Jersey, United States

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Daratumumab
Drug: Talquetamab
Drug: Teclistamab
Drug: Pomalidomide

First Posted Date: 2019-09-30

Last Posted Date: 2025-05-04

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 290

Registration Number: NCT04108195

Locations: 🇨🇦
Arthur J E Child Comprehensive Cancer Centre, Calgary, Alberta, Canada
🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
City of Hope Orange County Lennar Foundation Cancer Center, Irvine, California, United States

and more 21 locations

A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)

Phase 4

Active, not recruiting

Conditions: Prostatic Neoplasms

Interventions: Drug: Placebo
Drug: Apalutamide
Drug: Androgen-deprivation Therapy (ADT)

First Posted Date: 2019-09-30

Last Posted Date: 2025-05-25

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 75

Registration Number: NCT04108208

Locations: 🇨🇳
Hunan Cancer hospital, Changsha, China
🇨🇳
Fujian Medical University Union Hospital, Fuzhou, China
🇨🇳
Zhejiang Cancer Hospital, Hang Zhou, China

and more 24 locations

A Study Evaluating Participants With Moderately to Severely Active Crohn's Disease

Phase 2

Terminated

Conditions: Crohn Disease

Interventions: Drug: Placebo
Drug: JNJ-67864238

First Posted Date: 2019-09-25

Last Posted Date: 2025-02-04

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 48

Registration Number: NCT04102111

Locations: 🇺🇸
Peak Gastroenterology Associates, Colorado Springs, Colorado, United States
🇺🇸
Gastro Florida, Clearwater, Florida, United States
🇺🇸
Gastroenterology Associates of Central GA, Macon, Georgia, United States

and more 59 locations

A Study to Assess Interaction Between JNJ-64417184 and JNJ-53718678 After Single and Multiple Dosing in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: JNJ-53718678
Drug: JNJ-64417184

First Posted Date: 2019-09-16

Last Posted Date: 2025-02-03

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 16

Registration Number: NCT04090086

Locations: 🇳🇱
PRA Health Sciences Onderzoekscentrum Groningen, locatie Martini, Groningen, Netherlands

A Study of Bedaquiline 100 Milligram (mg) Tablets Administered as Different Test Formulations Compared to the Commercial Tablet Formulation (F001) in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Bedaquiline (Test formulation)
Drug: Bedaquiline (Reference formulation)

First Posted Date: 2019-09-12

Last Posted Date: 2025-02-03

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 36

Registration Number: NCT04087759

Locations: 🇧🇪
SGS Life Science Services, Antwerpen, Belgium

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy